Johnson & Johnson subsidiary Cilag GmbH International will pay a total of $330 million to AstraZeneca for rights to Rhinocort Aqua budesonide nasal spray outside of the US, AstraZeneca has announced. Cilag operates as part of J&J's Janssen Pharmaceutical Companies. A US J&J subsidiary, McNeil Consumer Healthcare, acquired US OTC rights to Rhinocort Aqua in 2014 and … [Read more...] about Cilag gets rights to Rhinocort Aqua outside of the US
Business
Mast Therapeutics to focus its efforts on AIR001
Mast Therapeutics has announced that it will stop its development program for vepoloxamer and will devote its resources to development of AIR001 sodium nitrite inhalation solution for patients with heart failure with preserved ejection fraction (HFpEF) and for pulmonary arterial hypertension (PAH). The company currently has 3 separate Phase 2 clinical trials of … [Read more...] about Mast Therapeutics to focus its efforts on AIR001
Aegis Therapeutics gets patent for octreotide nasal spray
The US Patent and Trademark Office (USPTO) has awarded US Patent No. 9,446,134 ("Stabilizing alkylglycoside compositions and methods thereof") to Aegis Therapeutics, the company said. The patent covers an intranasal formulation of octreotide, which is used to treat acromegaly and carcinoid syndrome. In July 2014, Aegis Therapeutics announced that it was looking to … [Read more...] about Aegis Therapeutics gets patent for octreotide nasal spray
Sumatriptan nasal spray shortage expected to be resolved by February 2017
According to an FDA drug shortages report, the US shortage of sumatriptan nasal spray due to a shortage of active ingredient that was first reported in November 2015 should be completely resolved by February 2017. At this time, both GlaxoSmithKline and Sandoz are reported to have 5 mg/spray versions of the nasal spray available, and GSK has the 20 mg product … [Read more...] about Sumatriptan nasal spray shortage expected to be resolved by February 2017
Medical Developments announces distribution deals, approval for Penthrox methoxyflurane inhaler
Purdue Pharma Canada will pay up to $3 million Canadian to Medical Developments International Limited (MDI) for Canadian rights to MDI's Penthrox methoxyflurane inhaler for the treatment of moderate to severe pain in trauma patients, and BL&H Co has obtained rights to the product in Korea, according to MDI. MDI also announced that Penthrox has been approved in the … [Read more...] about Medical Developments announces distribution deals, approval for Penthrox methoxyflurane inhaler
Orion to co-market Easyhaler DPIs with Menarini in several European countries
Orion Corporation has announced an agreement with Menarini Group to co-market its budesonide/formoterol Easyhaler DPI for the treatment of asthma and COPD in Germany, Italy, Spain, and Portugal. Each company will market the budesonide/formoterol inhaler under its own product name. Orion markets the DPI as Bufoler Easyhaler in the Netherlands, Fobuler in Italy, and … [Read more...] about Orion to co-market Easyhaler DPIs with Menarini in several European countries
Adherium announces management changes
Smartinhaler developer Adherium Limited has announced that Thomas Lynch has been appointed the company's new Chairman and that Doug Wilson will step down from the board to take on the role of Medical Director on a part time basis. Lynch recently retired from his role as Chair of ICON after serving on that company's board for over 20 years. He currently serves as … [Read more...] about Adherium announces management changes
Qualcomm to collaborate with Boehringer Ingelheim on connected Respimat inhaler
Boehringer Ingelheim and Qualcomm Life have agreed to collaborate on development of a disposable wireless data sensor module for BI's Respimat inhaler for COPD treatment. The sensor will connect with Qualcomm Life's 2net platform. Qualcomm had previously announced that it would develop a disposable sensor module for Novartis's Breezhaler. Boehringer Ingelheim … [Read more...] about Qualcomm to collaborate with Boehringer Ingelheim on connected Respimat inhaler
Cannabis Science says it will market cannabinoid MDI as rescue inhaler for asthma
Cannabis Science, which recently announced that it would introduce a THC/CBD product for use in nebulizers by asthma/COPD patients, now says that it plans to market a metered dose inhaler called the CBIS MDI Rescue Inhaler "to prevent or treat an asthma/COPD attack." According to the company, the inhalers will be "100 - 200 dose MDI with cannabinoid level … [Read more...] about Cannabis Science says it will market cannabinoid MDI as rescue inhaler for asthma
Arch Biopartners selects Catalent Inhalation to manufacture inhaled bactericidal drug
Arch Biopartners has announced that Catalent Inhalation will begin the process of manufacturing its AB569 bactericidal inhalation solution for use in trials of the drug in patients with antibiotic resistant lung infections. The process will start with formulation and stability studies and then move on to manufacture of clinical trial supplies, the company said. … [Read more...] about Arch Biopartners selects Catalent Inhalation to manufacture inhaled bactericidal drug